



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

2 6/1/89

Reagent: vPE5

Catalog Number: 355

Lot Number:

Provided: 1 vial cell-free virus at 5×10^9 infectious virions/ml.

Host or Recommended Host or Host Cells: HeLa and other vertebrate cells.

Cloning Vector: Vaccinia virus, strain WR.

Description: Plasmid pPE5 was used to construct the recombinant vaccinia virus vPE5. pPE5 contains the full length HIV-1 BH8 *env* gene cloned into the *Bam*HI site of pTF7-5. Expression is under control of the bacteriophage T7 promoter. This virus must be used in conjunction with another recombinant virus, vTF7-3 (catalog #356), which expresses T7 RNA polymerase.

Special Characteristics: Expression only occurs when cells are co-infected with a second vaccinia virus expressing bacteriophage T7 RNA polymerase (vTF7-3, catalog #356). The gp160 is glycosylated, processed, and inserted into the plasma membrane. Will form syncytia with human CD4 cells.
Cloning Site: Vaccinia virus thymidine kinase gene.

Recommended Storage: -70degreeC.

Contributor: Dr. Patricia Earl and Dr. Bernard Moss.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References:

Fuerst TR, Earl PL, Moss B. Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes. *Mol Cell Biol* **7**:2538-2544, 1987.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: vPE5 from Dr. Patricia Earl and Dr. Bernard Moss." Also include the reference cited above in any publications.

The US Government has submitted a patent application on this reagent.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact Dr. Sally Hu at the NIH Office of Technology Transfer, Email: hus@mail.nih.gov, Phone: 301-435-5606, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.

Last Updated:

June 24, 2013

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.